Isabelle Lamsoul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Isabelle Lamsoul has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Pierre G. Lutz
Univ Toulouse, Inserm, CNRS Infinity – Toulouse Institute for Infectious and Inflammatory Diseases Toulouse Occitanie France
30 shared publications Christel Moog-Lutz
18 shared publicationsArnaud Métais
Institut de Pharmacologie et de Biologie Structurale
14 shared publicationsCamille A. Spinner
12 shared publicationsChanaëlle Febrissy
11 shared publications- Mélina L. Heuzé
Université Paris cité, CNRS, Institut Jacques Monod, F-75013
5 shared publications
Latest Publications
- Open Access
- 29 October 2025
- Published by Wiley
Increasing filamins A and B in Th2 lymphocytes as a therapeutic opportunity to attenuate airway inflammation in mice
Background. Nearly half of asthmatic patients present a high type 2 inflammation initiated by the release of type 2 cytokines in the lungs. Th2 lymphocytes represent a major source of these cytokines and are key drivers of asthma pathogenesis. The ASB2α ubiquitin ligase is a positive regulator of Th2 lymphocyte functions that triggers degradation of filamins A and B (FLNa/b) leading to effective cell migration. Accordingly, loss of ASB2α in Th2 lymphocytes reduces their recruitment in inflamed lungs and attenuates airway inflammation in preclinical models of asthma. Here, we asked whether increasing FLNa/b levels in Th2 lymphocytes with pharmacological agents may represent a therapeutic opportunity to attenuate type 2 inflammation. Methods. A functional screen of library compounds was performed to identify small molecules that cause increased FLNa/b levels in ASB2α-expressing cells. In vitro experiments including immunological techniques and live imaging were used to investigate the effects of such hits in mouse primary Th2 lymphocytes. In vivo mouse models of airway inflammation and airway hyperreactivity were used to investigate the impact of these hits on type 2 inflammation. Results. The assay we developed led to the identification of two compounds, thiostrepton and oxibendazole, that reduce the dynamic migratory behavior of Th2 lymphocytes, and attenuate type 2 inflammation and airway hyperresponsiveness in mouse models of allergic airway inflammation. Conclusions. Our results show that augmenting FLNa/b levels in Th2 lymphocytes improves features of asthma, reinforcing the view that ASB2α and its substrates FLNa/b may represent novel pharmacological targets in type 2 pathologies.
- 29 October 2025
- Published by Wiley
Open AccessIncreasing filamins A and B in Th2 lymphocytes as a therapeutic opportunity to attenuate airway inflammation in mice
Background. Nearly half of asthmatic patients present a high type 2 inflammation initiated by the release of type 2 cytokines in the lungs. Th2 lymphocytes represent a major source of these cytokines and are key drivers of asthma pathogenesis. The ASB2α ubiquitin ligase is a positive regulator of Th2 lymphocyte functions that triggers degradation of filamins A and B (FLNa/b) leading to effective cell migration. Accordingly, loss of ASB2α in Th2 lymphocytes reduces their recruitment in inflamed lungs and attenuates airway inflammation in preclinical models of asthma. Here, we asked whether increasing FLNa/b levels in Th2 lymphocytes with pharmacological agents may represent a therapeutic opportunity to attenuate type 2 inflammation. Methods. A functional screen of library compounds was performed to identify small molecules that cause increased FLNa/b levels in ASB2α-expressing cells. In vitro experiments including immunological techniques and live imaging were used to investigate the effects of such hits in mouse primary Th2 lymphocytes. In vivo mouse models of airway inflammation and airway hyperreactivity were used to investigate the impact of these hits on type 2 inflammation. Results. The assay we developed led to the identification of two compounds, thiostrepton and oxibendazole, that reduce the dynamic migratory behavior of Th2 lymphocytes, and attenuate type 2 inflammation and airway hyperresponsiveness in mouse models of allergic airway inflammation. Conclusions. Our results show that augmenting FLNa/b levels in Th2 lymphocytes improves features of asthma, reinforcing the view that ASB2α and its substrates FLNa/b may represent novel pharmacological targets in type 2 pathologies.
- Open Access
- 5 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Fine-tuning levels of filamins a and b as a specific mechanism sustaining Th2 lymphocyte functions
Augmenting the portfolio of therapeutics for type 2-driven diseases is crucial to address unmet clinical needs and to design personalized treatment schemes. An attractive therapy for such diseases would consist in targeting the recruitment of T helper 2 (Th2) lymphocytes to inflammatory sites. Herein, we show the degradation of filamins (FLN) a and b by the ASB2α E3 ubiquitin ligase as a mechanism sustaining Th2 lymphocyte functions. Low levels of FLNa and FLNb confer an elongated shape to Th2 lymphocytes associated with efficient αVβ3 integrin-dependent cell migration. Genes encoding the αVβ3 integrin and ASB2α belong to the core of Th2-specific genes. Using genetically modified mice, we find that increasing the levels of FLNa and FLNb in Th2 lymphocytes reduces airway inflammation through diminished Th2 lymphocyte recruitment in inflamed lungs. Collectively, our results highlight ASB2α and its substrates FLNa and FLNb to alter Th2 lymphocyte-mediated responses.
- 5 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessFine-tuning levels of filamins a and b as a specific mechanism sustaining Th2 lymphocyte functions
Augmenting the portfolio of therapeutics for type 2-driven diseases is crucial to address unmet clinical needs and to design personalized treatment schemes. An attractive therapy for such diseases would consist in targeting the recruitment of T helper 2 (Th2) lymphocytes to inflammatory sites. Herein, we show the degradation of filamins (FLN) a and b by the ASB2α E3 ubiquitin ligase as a mechanism sustaining Th2 lymphocyte functions. Low levels of FLNa and FLNb confer an elongated shape to Th2 lymphocytes associated with efficient αVβ3 integrin-dependent cell migration. Genes encoding the αVβ3 integrin and ASB2α belong to the core of Th2-specific genes. Using genetically modified mice, we find that increasing the levels of FLNa and FLNb in Th2 lymphocytes reduces airway inflammation through diminished Th2 lymphocyte recruitment in inflamed lungs. Collectively, our results highlight ASB2α and its substrates FLNa and FLNb to alter Th2 lymphocyte-mediated responses.
- Open Access
- 15 March 2024
- Published by Springer Nature in Research Square
Fine-Tuning Levels of Filamins A and B as a Specific Mechanism Sustaining Th2 Lymphocyte Functions
Augmenting the portfolio of therapeutics for type 2-driven diseases is crucial to address unmet clinical needs and to design personalized treatment schemes. An attractive therapy for such diseases would consist in targeting the recruitment of T helper 2 (Th2) lymphocytes to inflammatory sites. Herein, we unravel the degradation of filamins (FLN) A and B by the ASB2α E3 ubiquitin ligase as a mechanism sustaining Th2 lymphocyte functions. Low levels of FLNa and FLNb confer an elongated shape to Th2 lymphocytes associated with efficient αVβ3 integrin-dependent cell migration. Genes encoding the αVβ3 integrin and ASB2α belong to the core of Th2-specific genes. Using genetically modified mice or the small molecule thiostrepton, we find that increasing the levels of FLNa and FLNb in Th2 lymphocytes reduces airway inflammation through diminished Th2 lymphocyte recruitment in inflamed lungs. Collectively, our results highlight ASB2α and its substrates FLNa and FLNb to rewire Th2 lymphocyte-mediated responses.
- 15 March 2024
- Published by Springer Nature in Research Square
Open AccessFine-Tuning Levels of Filamins A and B as a Specific Mechanism Sustaining Th2 Lymphocyte Functions
Augmenting the portfolio of therapeutics for type 2-driven diseases is crucial to address unmet clinical needs and to design personalized treatment schemes. An attractive therapy for such diseases would consist in targeting the recruitment of T helper 2 (Th2) lymphocytes to inflammatory sites. Herein, we unravel the degradation of filamins (FLN) A and B by the ASB2α E3 ubiquitin ligase as a mechanism sustaining Th2 lymphocyte functions. Low levels of FLNa and FLNb confer an elongated shape to Th2 lymphocytes associated with efficient αVβ3 integrin-dependent cell migration. Genes encoding the αVβ3 integrin and ASB2α belong to the core of Th2-specific genes. Using genetically modified mice or the small molecule thiostrepton, we find that increasing the levels of FLNa and FLNb in Th2 lymphocytes reduces airway inflammation through diminished Th2 lymphocyte recruitment in inflamed lungs. Collectively, our results highlight ASB2α and its substrates FLNa and FLNb to rewire Th2 lymphocyte-mediated responses.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S1 shows the numbers of dendritic cells, macrophages and B cells in the colon, and the numbers of dendritic cells in the mesenteric lymph nodes of control and cKO mice treated with AOM and DSS.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S1 shows the numbers of dendritic cells, macrophages and B cells in the colon, and the numbers of dendritic cells in the mesenteric lymph nodes of control and cKO mice treated with AOM and DSS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S2 shows the numbers of γÎ' T, IFN-γ+ γÎ' T, NK and IFN-γ+ NK cells in the colon of control and cKO mice treated with AOM and DSS.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S2 shows the numbers of γÎ' T, IFN-γ+ γÎ' T, NK and IFN-γ+ NK cells in the colon of control and cKO mice treated with AOM and DSS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S1 shows the numbers of dendritic cells, macrophages and B cells in the colon, and the numbers of dendritic cells in the mesenteric lymph nodes of control and cKO mice treated with AOM and DSS.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S1 shows the numbers of dendritic cells, macrophages and B cells in the colon, and the numbers of dendritic cells in the mesenteric lymph nodes of control and cKO mice treated with AOM and DSS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
The escape of cancer cells from host immunosurveillance involves a shift in immune responses, including an imbalance in Th1 and Th2 cells. A Th1-dominated immune response predicts positive outcomes in colorectal cancer. The E3 ubiquitin ligase, Asb2α, is expressed in Th2 cells, but its roles in T-cell maturation and cancer are unclear. We provide evidence that the Th2 master regulator, Gata3, induces Asb2. Loss of Asb2 did not affect Th differentiation ex vivo, but reduced IL4 production from Th2 cells. We found that high ASB2 expression was associated with poor outcome in colorectal cancer. Loss of Asb2 from hematopoietic cells promoted a Th1 response and attenuated colitis-associated tumorigenesis in mice. Diminished Th2 function correlated with increased IFNγ production and an enhanced type 1 antitumor immune response in Asb2-deficient mice. Our work suggests that Asb2α promotes a Th2 phenotype in vivo, which in turn is associated with tumor progression in a mouse model of colitis.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
The escape of cancer cells from host immunosurveillance involves a shift in immune responses, including an imbalance in Th1 and Th2 cells. A Th1-dominated immune response predicts positive outcomes in colorectal cancer. The E3 ubiquitin ligase, Asb2α, is expressed in Th2 cells, but its roles in T-cell maturation and cancer are unclear. We provide evidence that the Th2 master regulator, Gata3, induces Asb2. Loss of Asb2 did not affect Th differentiation ex vivo, but reduced IL4 production from Th2 cells. We found that high ASB2 expression was associated with poor outcome in colorectal cancer. Loss of Asb2 from hematopoietic cells promoted a Th1 response and attenuated colitis-associated tumorigenesis in mice. Diminished Th2 function correlated with increased IFNγ production and an enhanced type 1 antitumor immune response in Asb2-deficient mice. Our work suggests that Asb2α promotes a Th2 phenotype in vivo, which in turn is associated with tumor progression in a mouse model of colitis.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
The escape of cancer cells from host immunosurveillance involves a shift in immune responses, including an imbalance in Th1 and Th2 cells. A Th1-dominated immune response predicts positive outcomes in colorectal cancer. The E3 ubiquitin ligase, Asb2α, is expressed in Th2 cells, but its roles in T-cell maturation and cancer are unclear. We provide evidence that the Th2 master regulator, Gata3, induces Asb2. Loss of Asb2 did not affect Th differentiation ex vivo, but reduced IL4 production from Th2 cells. We found that high ASB2 expression was associated with poor outcome in colorectal cancer. Loss of Asb2 from hematopoietic cells promoted a Th1 response and attenuated colitis-associated tumorigenesis in mice. Diminished Th2 function correlated with increased IFNγ production and an enhanced type 1 antitumor immune response in Asb2-deficient mice. Our work suggests that Asb2α promotes a Th2 phenotype in vivo, which in turn is associated with tumor progression in a mouse model of colitis.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
The escape of cancer cells from host immunosurveillance involves a shift in immune responses, including an imbalance in Th1 and Th2 cells. A Th1-dominated immune response predicts positive outcomes in colorectal cancer. The E3 ubiquitin ligase, Asb2α, is expressed in Th2 cells, but its roles in T-cell maturation and cancer are unclear. We provide evidence that the Th2 master regulator, Gata3, induces Asb2. Loss of Asb2 did not affect Th differentiation ex vivo, but reduced IL4 production from Th2 cells. We found that high ASB2 expression was associated with poor outcome in colorectal cancer. Loss of Asb2 from hematopoietic cells promoted a Th1 response and attenuated colitis-associated tumorigenesis in mice. Diminished Th2 function correlated with increased IFNγ production and an enhanced type 1 antitumor immune response in Asb2-deficient mice. Our work suggests that Asb2α promotes a Th2 phenotype in vivo, which in turn is associated with tumor progression in a mouse model of colitis.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S2 shows the numbers of γÎ' T, IFN-γ+ γÎ' T, NK and IFN-γ+ NK cells in the colon of control and cKO mice treated with AOM and DSS.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer
Figure S2 shows the numbers of γÎ' T, IFN-γ+ γÎ' T, NK and IFN-γ+ NK cells in the colon of control and cKO mice treated with AOM and DSS.